UBS Upgrades AstraZeneca PLC - Depositary Receipt

UBS Upgrades AstraZeneca PLC - Depositary Receipt () (AZN)
Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () (NasdaqGS:AZN) from Neutral to Buy. Analyst Price Forecast Suggests 13.43% Upside As of January 29,
Sumitomo Mitsui Trust Group Inc. Has $5.58 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
AstraZeneca PLC (AZN): Among the Best International Dividend Stocks to Buy Now
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other international dividend stocks.
Stephens Inc. AR Trims Position in AstraZeneca PLC (NASDAQ:AZN)
Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s stock after selling 1,
AstraZeneca upgraded to Buy from Neutral at UBS
UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s
AstraZeneca upgraded by UBS to buy on growth potential
UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the oncology drug Imfinzi are $1B ahead of consensus on new small cell lung and bladder cancer indications,
Business Insider4d
AstraZeneca PLC Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and ...
AstraZeneca Stock Rally Will be Tested by Answers on China Probe
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
Morningstar10d
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit. IF YOU ...
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
cnbctv182d
AstraZeneca Pharma Q3 Results: Profit nearly doubles, margin expands sharply
Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.
AstraZeneca's cancer drug tops list of new brands launched in 2024
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Morgan Stanley sets AstraZeneca stock Overweight with £145 target
AstraZeneca PLC (LON:AZN:LN) (NASDAQ: AZN), a pharmaceutical giant with a market capitalization of $224.5 billion, received a new Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a ...